Market Research Report
Diabetes Care Drugs Market (2012 - 2024)
|Published by||Mordor Intelligence LLP||Product code||390670|
|Published||Content info||110 Pages
Delivery time: 1-2 business days
|Diabetes Care Drugs Market (2012 - 2024)|
|Published: February 1, 2019||Content info: 110 Pages||
The market size, in 2017, for the global diabetes drugs market was registered to be USD 67,510.43 million, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
North America dominates the market, followed by Asia-Pacific.
Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body's cells do not respond properly to insulin (known as Type 2 diabetes), or both.
Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.
The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.
As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, the growing prevalence of obesity, and technological advancements are further driving the market.
In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.
There have been constant innovations driven by manufacturers to compete and struggle in the market.
Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
In 2015 and 2016, Lantus global sales were down by 11%, due to competition from other new drugs, biosimilars, and its own brand Toujeo.
September 2017: Insulin Tregopil, the first Oral Insulin, was under development by Biocon India, which is supported by JDRF.
March 2017: Zynquista (Sotagliflozin) was the first oral anti-diabetic drug approved in the United States for use by adults with Type 1 diabetes.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client's requirements
3 months of analyst support